Advertisement

Update on Optic Neuritis in Adults

Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
  • Serena Li
    Affiliations
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

    Gonville and Caius College, University of Cambridge, Trinity Street, Cambridge, CB2 1TA, United Kingdom
    Search for articles by this author
  • Rahul A. Sharma
    Affiliations
    Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada

    Prism Eye Institute, 2201 Bristol Circle Suite 100, Oakville, Ontario, L6H 0J8, Canada
    Search for articles by this author
  • Benson S. Chen
    Correspondence
    Corresponding author. Gonville and Caius College, University of Cambridge, Trinity Street, Cambridge, CB2 1TA, United Kingdom.
    Affiliations
    Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

    Cambridge Eye Unit, Addenbrooke’s Hospital, CUH-NHS, Cambridge, United Kingdom

    Gonville and Caius College, University of Cambridge, Trinity Street, Cambridge, CB2 1TA, United Kingdom
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Ophthalmology and Optometry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hor J.Y.
        • Asgari N.
        • Nakashima I.
        • et al.
        Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide.
        Front Neurol. 2020; 11: 501
        • Chen J.J.
        • Bhatti M.T.
        Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
        Curr Opin Neurol. 2020; 33: 47-54
        • Optic Neuritis Study Group
        The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial.
        Arch Ophthalmol. 1991; 109: 1673-1678
        • Chen J.J.
        • Flanagan E.P.
        • Jitprapaikulsan J.
        • et al.
        Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome.
        Am J Ophthalmol. 2018; 195: 8-15
        • Morrow S.A.
        • Fraser J.A.
        • Day C.
        • et al.
        Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids: a randomized clinical trial.
        JAMA Neurol. 2018; 75: 690-696
        • Filippatou A.G.
        • Mukharesh L.
        • Saidha S.
        • et al.
        AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis.
        Front Neurol. 2020; 11: 540156
        • Akaishi T.
        • Himori N.
        • Takeshita T.
        • et al.
        Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease.
        Mult Scler Relat Disord. 2021; 56: 103222
        • Matiello M.
        • Lennon V.A.
        • Jacob A.
        • et al.
        NMO-IgG predicts the outcome of recurrent optic neuritis.
        Neurology. 2008; 70: 2197-2200
        • Keltner J.L.
        • Johnson C.A.
        • Cello K.E.
        • et al.
        Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years.
        Arch Ophthalmol. 2010; 128: 330-337
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Kupersmith M.J.
        • Alban T.
        • Zeiffer B.
        • et al.
        Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance.
        Brain. 2002; 125: 812-822
        • Shor N.
        • Deschamps R.
        • Cobo Calvo A.
        • et al.
        MRI characteristics of MOG-Ab associated disease in adults: an update.
        Rev Neurol (Paris). 2021; 177: 39-50
        • Ramanathan S.
        • Prelog K.
        • Barnes E.H.
        • et al.
        Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis.
        Mult Scler. 2016; 22: 470-482
        • Chen J.J.
        • Tobin W.O.
        • Majed M.
        • et al.
        Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial.
        JAMA Ophthalmol. 2018; 136: 419-422
        • Sechi E.
        • Buciuc M.
        • Pittock S.J.
        • et al.
        Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing.
        JAMA Neurol. 2021; 78: 741-746
        • Jarius S.
        • Paul F.
        • Aktas O.
        • et al.
        MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
        J Neuroinflammation. 2018; 15: 134
        • Gal R.L.
        • Vedula S.S.
        • Beck R.
        Corticosteroids for treating optic neuritis.
        Cochrane Database Syst Rev. 2015; 8: CD001430
        • Stiebel-Kalish H.
        • Hellmann M.A.
        • Mimouni M.
        • et al.
        Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?.
        Neurol Neuroimmunol Neuroinflamm. 2019; 6: e572
        • Akaishi T.
        • Takeshita T.
        • Himori N.
        • et al.
        Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD.
        Front Neurol. 2020; 11: 932
        • Bonnan M.
        • Valentino R.
        • Debeugny S.
        • et al.
        Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.
        J Neurol Neurosurg Psychiatry. 2018; 89: 346-351
        • Deschamps R.
        • Gueguen A.
        • Parquet N.
        • et al.
        Plasma exchange response in 34 patients with severe optic neuritis.
        J Neurol. 2016; 263: 883-887
        • Elsone L.
        • Panicker J.
        • Mutch K.
        • et al.
        Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.
        Mult Scler. 2014; 20: 501-504
        • Optic Neuritis Study G.
        Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up.
        Arch Neurol. 2008; 65: 727-732
        • Rae-Grant A.
        • Day G.S.
        • Marrie R.A.
        • et al.
        Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology.
        Neurology. 2018; 90: 777-788
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Pittock S.J.
        • Zekeridou A.
        • Weinshenker B.G.
        Hope for patients with neuromyelitis optica spectrum disorders: from mechanisms to trials.
        Nat Rev Neurol. 2021; 17: 759-773
        • Weinshenker B.G.
        • Wingerchuk D.M.
        Neuromyelitis spectrum disorders.
        Mayo Clin Proc. 2017; 9: 663-679
        • Poupart J.
        • Giovannelli J.
        • Deschamps R.
        • et al.
        Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
        Neurology. 2020; 94: e1645-e1656
        • Giovannelli J.
        • Ciron J.
        • Cohen M.
        • et al.
        A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
        Ann Clin Transl Neurol. 2021; 8: 2025-2037
        • Marignier R.
        • Hacohen Y.
        • Cobo-Calvo A.
        • et al.
        Myelin-oligodendrocyte glycoprotein antibody-associated disease.
        Lancet Neurol. 2021; 20: 762-772
        • Ringelstein M.
        • Ayzenberg I.
        • Lindenblatt G.
        • et al.
        Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders.
        Neurol Neuroimmunol Neuroinflamm. 2022; 9: e1100
        • Costello F.
        • Coupland S.
        • Hodge W.
        • et al.
        Quantifying axonal loss after optic neuritis with optical coherence tomography.
        Ann Neurol. 2006; 59: 963-969
        • Akaishi T.
        • Nakashima I.
        • Takeshita T.
        • et al.
        Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica.
        J Neuroimmunol. 2016; 293: 28-33
        • Akaishi T.
        • Takahashi T.
        • Nakashima I.
        • et al.
        Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD).
        J Neurol Sci. 2020; 410: 116671